Page last updated: 2024-11-05

styrene oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Styrene oxide is an organic compound with the formula C6H5CHCH2O. It is a colorless liquid with a pungent odor. It is produced industrially by the epoxidation of styrene with hydrogen peroxide. Styrene oxide is a highly reactive compound and is used as an intermediate in the synthesis of various chemicals, including polymers, resins, and pharmaceuticals. It is also used as a fumigant and an insecticide. Styrene oxide is a known human carcinogen and is toxic to the environment. It is the subject of much research due to its environmental impact and its potential use in various applications. Extensive research has been conducted on the synthesis, toxicity, environmental fate, and potential applications of styrene oxide. This research is driven by the need to understand the potential risks associated with this compound and to develop safer and more sustainable alternatives.'

styrene oxide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

styrene oxide : An epoxide that is oxirane in which one of the hydrogens has been replaced by a phenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7276
CHEMBL ID1605493
CHEBI ID17907
SCHEMBL ID21026
MeSH IDM0061643

Synonyms (107)

Synonym
nsc-7582
nsc7582
1,2-epoxy-1-phenylethane
1,2-epoxyethylbenzene
CHEBI:17907 ,
alpha,beta-epoxystyrene
epoxyethylbenzene
C0037
NCGC00091674-01
hsdb 2646
ccris 1268
einecs 202-476-7
nsc 637
ep-182
benzene, (1,2-epoxyethyl)-
fenyloxiran [czech]
brn 0108582
ai3-18151
epoxyethyl benzene
benzene, (epoxyethyl)-
epoxystyrene
nsc637
styryl oxide
2-phenyloxirane ,
nci-c54977
wln: t3otj br
1-phenyloxirane
styrene epoxide
styrene 7,8-oxide
(1,2-epoxyethyl)benzene
phenylethylene oxide
oxirane, phenyl-
1-phenyl-1,2-epoxyethane
phenyloxirane
96-09-3
styrene-7,8-oxide
nsc-637
phenyl oxirane
.alpha.,.beta.-epoxystyrene
(epoxyethyl)benzene
phenethylene oxide
C02083
styrene oxide
styrene oxide, >=97%
styrene oxide, 97%
styrene oxide, (r)-isomer
styrene oxide, (+-)-isomer
styrene oxide, (s)-isomer
E0013
AKOS000120666
CHEMBL1605493
NCGC00091674-02
NCGC00091674-03
NCGC00259661-01
tox21_300110
NCGC00253978-01
cas-96-09-3
tox21_202112
dtxcid301286
dtxsid2021286 ,
2-phenyl-oxirane
FT-0674671
STL146352
9qh06ngt6o ,
ec 202-476-7
5-17-01-00577 (beilstein handbook reference)
unii-9qh06ngt6o
fenyloxiran
oxirane, 2-phenyl-
FT-0605077
FT-0605345
styreneoxide
BP-21407
SCHEMBL21026
ethane, 1,2-epoxy-1-phenyl-
(+/-)-styrene oxide
(+/-)-phenyloxirane
styrene oxide [inci]
styrene-7,8-oxide [iarc]
styrene oxide [hsdb]
J-503834
racemic styrene oxide
1,2-epoxyethyl benzene
(+/-)-phenylethylene oxide
(+)-styrene oxide
racemic phenyloxirane
phenyl-ethylene oxide
(rac) phenylethylenoxide
2-(phenyl)oxirane
AKOS016843291
(.+/-.)-styrene oxide
mfcd00005121
F0001-2287
AC-9511
AC-9510
EN300-20996
styrene 0xide
a,b-epoxystyrene
FT-0674672
Q413262
SY033347
SY032955
BCP14534
rac styrene oxide
styrene oxide-d8, 97+ atom % d
25189-69-9
Z104486008

Research Excerpts

Overview

Styrene oxide is a versatile electrophile causing numerous adducts. cisplatin has a high specificity towards guanine-N-7 and cross-link formation.

ExcerptReferenceRelevance
"Styrene oxide proved also to be a very potent inducer of sister chromatid exchanges (SCE) within the concentration range 5 X 10(-6) to 1 X 10(-3) mol."( Cytogenetic analysis of human peripheral blood lymphocytes in culture exposed in vitro to styrene and styrene oxide.
Pohlová, H; Rössner, P; Srám, RJ, 1984
)
1.2
"Styrene oxide is a versatile electrophile causing numerous adducts; cisplatin has a high specificity towards guanine-N-7 and cross-link formation."( DNA adducts in experimental cancer research.
Försti, A; Hemminki, K; Mustonen, R; Savela, K, 1986
)
0.99

Effects

Styrene oxide has two optical isomers and it was reported that the (R)-enantiomer was more toxic than the (S)-en Antiomer. Styrene oxides have been tested for toxicity and mutation in a liquid suspension assay.

ExcerptReferenceRelevance
"Styrene oxide has two optical isomers and it was reported that the (R)-enantiomer was more toxic than the (S)-enantiomer."( Development of enantioselective polyclonal antibodies to detect styrene oxide protein adducts.
Chai, X; Gee, S; Hammock, BD; Shen, S; Tian, Y; Zeng, S; Zhang, F; Zheng, J, 2009
)
1.31
"Styrene oxides have been tested for toxicity and mutation in a liquid suspension assay using Escherichia coli WP2 and some of its repair deficient derivatives."( Mutagenicities of styrene oxide derivatives on bacterial test systems: relationship between mutagenic potencies and chemical reactivity.
Goto, M; Sugiura, K, 1981
)
1.32

Toxicity

ExcerptReferenceRelevance
"Inhaled styrene is known to be toxic to the nasal olfactory epithelium of both mice and rats, although mice are markedly more sensitive."( The toxicity of styrene to the nasal epithelium of mice and rats: studies on the mode of action and relevance to humans.
Foster, J; Green, T; Lee, R; Lund, V; Meadowcroft, S; Toghill, A, 2001
)
0.31
" These findings would suggest that there should be no difference in the toxic responses to styrene between these two strains."( Comparison of the susceptibility of wild-type and CYP2E1 knockout mice to the hepatotoxic and pneumotoxic effects of styrene and styrene oxide.
Carlson, GP, 2004
)
0.53
" The diversity of their modes of toxic action further complicates effect assessment and calls for methods yielding additional information on the mechanisms of toxicity."( Mechanistic approaches for evaluating the toxicity of reactive organochlorines and epoxides in green algae.
Behra, R; Escher, BI; Harder, A; Niederer, C; Schwarzenbach, RP, 2004
)
0.32
"Styrene has been found to be toxic to the respiratory system, and the toxicity of styrene is metabolism-dependent."( Investigation of bioactivation and toxicity of styrene in CYP2E1 transgenic cells.
Chung, JK; Liu, G; Yuan, W; Zheng, J, 2006
)
0.33
" Although the toxic effects of styrene have been extensively documented, the molecular mechanisms responsible for SO-induced neurotoxicity are still unclear."( Synaptic contacts impaired by styrene-7,8-oxide toxicity.
Assennato, G; Corsi, P; Costa, GL; D'Aprile, A; Nico, B, 2007
)
0.34
"Styrene, which is widely used in manufacturing, is both acutely and chronically toxic to mice."( Metabolism and toxicity of styrene in microsomal epoxide hydrolase-deficient mice.
Carlson, GP, 2010
)
0.36
" The basis for the unusual greater toxicity of S-SO, rather than the generally more toxic R-SO, in mEH-/- mice may be related to differences in detoxification by EH."( Comparison of styrene oxide enantiomers for hepatotoxic and pneumotoxic effects in microsomal epoxide hydrolase-deficient mice.
Carlson, GP, 2011
)
0.73
"Styrene is known to be hepatotoxic and pneumotoxic in rodents, and these adverse effects are related to its metabolism."( Hepatotoxicity and pneumotoxicity of styrene and its metabolites in glutathione S-transferase-deficient mice.
Carlson, GP, 2011
)
0.37
" S and its alkene-oxidized metabolite styrene oxide (SO) were not lung toxic in CYP2F2(-/-) [knockout] mice, indicating S-induced mouse lung tumors are mediated through mouse-specific CYP2F2-generated ring-oxidized metabolite(s) in lung bronchioles."( Studies of styrene, styrene oxide and 4-hydroxystyrene toxicity in CYP2F2 knockout and CYP2F1 humanized mice support lack of human relevance for mouse lung tumors.
Banton, M; Bus, J; Cruzan, G; Hotchkiss, J; Moore, C; Sarang, S; Sura, R; Yost, G, 2013
)
0.98
" The chemicals might have major adverse effects on the functions of the organelles in hepatocytes such as mitochondria, but little influence to the cell membrane damage."( [Optimization of primary hepatocytes model and study on the cytotoxicity of styrene and styrene oxide].
Bin, P; Dai, Y; Ji, Y; Meng, T; Miao, P; Niu, Y; Zheng, Y, 2016
)
0.66

Pharmacokinetics

ExcerptReferenceRelevance
" To estimate the body burden of SO resulting from various scenarios, a physiologically based pharmacokinetic (PBPK) model for ST and its metabolite SO was developed."( A physiologic pharmacokinetic model for styrene and styrene-7,8-oxide in mouse, rat and man.
Csanády, GA; Filser, JG; Mendrala, AL; Nolan, RJ, 1994
)
0.29
" A mode of action-based physiologically based pharmacokinetic (PBPK) model was developed to predict the concentration of ST and SO in blood, liver, and the respiratory-tract tissues, particularly in terminal bronchioles (target tisue), in order to conduct interspecies extrapolations and determine the extent to which there is a pharmacokinetic basis for the observed species specificity."( Physiologically based pharmacokinetic modeling of styrene and styrene oxide respiratory-tract dosimetry in rodents and humans.
Andersen, ME; Clewell, HJ; Cruzan, G; Sarangapani, R; Teeguarden, JG, 2002
)
0.56

Dosage Studied

Urine of rats dosed with styrene (240 mg/kg) was analysed for mandelic acid enantiomers and for regioisomers and diastereomers of mercapturic acids by NMR spectrometry. The inhibition by styrene oxide had a clear dose-response relationship.

ExcerptRelevanceReference
" The inhibition by styrene oxide had a clear dose-response relationship, but that by styrene did not."( [Inhibition of delta-aminolevulinic acid dehydratase by styrene and styrene oxide].
Fujishiro, K; Inoue, N; Mori, K, 1988
)
0.84
" Blood samples were collected 6 and 24 h after treatment for studies of dose-response and 6 h to 32 days after treatment for studies of adduct stability."( Dosimetry of styrene 7,8-oxide in styrene- and styrene oxide-exposed mice and rats by quantification of haemoglobin adducts.
Christakopoulos, A; Osterman-Golkar, S; Svensson, K; Zorcec, V, 1995
)
0.55
" In addition, a nonlinear dose-response was observed where toxicity and mortality were greater in mice exposed to 250 ppm than in those exposed to 500 ppm."( Styrene inhalation toxicity studies in mice. II. Sex differences in susceptibility of B6C3F1 mice.
Adkins, B; Dill, JA; Mahler, JF; Morgan, DL; O'Connor, RW; Price, HC, 1993
)
0.29
"50 mCi/g, ip) at intervals from 1 to 48 hr after dosing with SO."( Cell proliferation in rat forestomach following oral administration of styrene oxide.
Cope, C; Cruzan, G; Dalbey, WE; Rodriguez, SC, 1996
)
0.53
" In the dose-range studied, for all adducts a clear dose-response relationship was observed."( Adduct formation on DNA and haemoglobin in mice intraperitoneally administered with styrene.
Hemminki, K; Pauwels, W; Plná, K; Severi, M; Veulemans, H; Vodicèka, P, 1996
)
0.29
"Urine of rats dosed with styrene (240 mg/kg), R-, S- and racemic styrene oxide (150 mg/kg) was analysed for mandelic acid enantiomers and for regioisomers and diastereomers of mercapturic acids by NMR spectrometry."( Stereochemical aspects of styrene biotransformation.
Linhart, I; Mládková, I; Smejkal, J, 1998
)
0.54
" A strong sublinear dose-response relationship was observed in the lymphocytes, liver and bone marrow cells, possibly indicating a saturation of the detoxifying enzyme systems in these organs."( Detection of styrene and styrene oxide-induced DNA damage in various organs of mice using the comet assay.
Hellman, B; Vaghef, H, 1998
)
0.6
" However, these olefins were not detected in the urine or feces of antibiotics-treated rats dosed with cis- or trans-stilbene oxide."( Reductive metabolism of stilbene oxide and styrene oxide to the olefins in rats.
Kitamura, S; Maeda, C; Mita, M; Shiraishi, Y; Sueki, H; Tatsumi, K, 2000
)
0.57
" In the present article, we propose a model to fit dose-response curves in vitro."( Models of neurotoxicity: extrapolation of benchmark doses in vitro.
Alinovi, R; Caglieri, A; Ceccatelli, S; Goldoni, M; Mutti, A; Vettori, MV, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.31620.003245.467312,589.2998AID2517
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.19330.006038.004119,952.5996AID1159521
AR proteinHomo sapiens (human)Potency0.58580.000221.22318,912.5098AID743063
thyroid stimulating hormone receptorHomo sapiens (human)Potency12.58930.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency12.99880.000657.913322,387.1992AID1259394
retinoid X nuclear receptor alphaHomo sapiens (human)Potency19.01140.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.43540.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency20.78540.000229.305416,493.5996AID743078
aryl hydrocarbon receptorHomo sapiens (human)Potency61.50380.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency68.58960.001723.839378.1014AID743083
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1517970Inhibition of human FBPase expressed in Escherichia coli BL21 (DE3) at 500 uM using FBP as substrate incubated for 5 mins by malachite green dye based spectrophotometry relative to control2019European journal of medicinal chemistry, Dec-15, Volume: 184Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects.
AID1594610Drug reactivity against serine in PBS buffer by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
AID1594614Reversible drug reactivity against serine in PBS buffer by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
AID1594609Drug reactivity against cysteine in PBS buffer by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
AID1594613Reversible drug reactivity against cysteine in PBS buffer by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (438)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990106 (24.20)18.7374
1990's113 (25.80)18.2507
2000's125 (28.54)29.6817
2010's78 (17.81)24.3611
2020's16 (3.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.12 (24.57)
Research Supply Index6.14 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index77.33 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.43%)5.53%
Reviews11 (2.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other449 (97.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]